These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29465259)

  • 1. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
    Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
    O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
    Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Assefa Y; Assefa Y; Woldeyohannes S; Hamada Y; Getahun H
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
    Menzies D; Long R; Trajman A; Dion MJ; Yang J; Al Jahdali H; Memish Z; Khan K; Gardam M; Hoeppner V; Benedetti A; Schwartzman K
    Ann Intern Med; 2008 Nov; 149(10):689-97. PubMed ID: 19017587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
    Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
    Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Side Effects of Rifampin versus Isoniazid in Children.
    Diallo T; Adjobimey M; Ruslami R; Trajman A; Sow O; Obeng Baah J; Marks GB; Long R; Elwood K; Zielinski D; Gninafon M; Wulandari DA; Apriani L; Valiquette C; Fregonese F; Hornby K; Li PZ; Hill PC; Schwartzman K; Benedetti A; Menzies D
    N Engl J Med; 2018 Aug; 379(5):454-463. PubMed ID: 30067928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Question 1: what are the options for treating latent TB infection in children?
    Gwee A; Coghlan B; Curtis N
    Arch Dis Child; 2013 Jun; 98(6):468-74. PubMed ID: 23661667
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.